Analysts surveyed by FactSet are anticipating adjusted earnings of $4.97 per share on $2.91 billion in revenue. For the year-ago period, Biogen reported adjusted earnings of $4.48 per share on revenue of $2.78 billion.
Leerink recently reiterated a "market perform" rating and $367 price target on the stock, noting that Biogen's neuropathic pain treatment candidate raxatrigine faces "long odds."
"We don't believe that sufficient proof of concept or re-risking has been established for this product, or this class, to justify including revenue, or value, for raxatrigine in our current company model for Biogen," the firm wrote in a note.
Biogen stock was down in late-afternoon trading on Monday.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
Biogen's strengths such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures outweigh the fact that the company shows weak operating cash flow.
You can view the full analysis from the report here: BIIB
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.